Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2018

Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

September 30, 2018	Level 1		Level 2		Level 3		Total
Assets
Cash	$	2,936	$	—	$	—	$	2,936
Money market securities (cash equivalents)		8,819		—		—		8,819
Restricted cash (Note 6)		50		—		—		50
Corporate bonds and commercial paper (short term investments)		—		1,390		—		1,390
Total assets	$	11,805	$	1,390	$	—	$	13,195

Summary of Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments consist of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
September 30, 2018	Cost		Gains		Losses		Fair Value
Cash	$	2,936	$	—	$	—	$	2,936
Money market securities		8,819		—		—		8,819
Total cash and cash equivalents	$	11,755	$	—	$	—	$	11,755
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50
Corporate bonds and commercial paper	$	1,390		—		—	$	1,390
Total short-term investments	$	1,390	$	—	$	—	$	1,390